Castle Biosciences (CSTL) Operating Income (2018 - 2025)
Historic Operating Income for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to -$6.8 million.
- Castle Biosciences' Operating Income fell 23396.34% to -$6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$34.9 million, marking a year-over-year decrease of 326541.43%. This contributed to the annual value of $8.7 million for FY2024, which is 11275.43% up from last year.
- Castle Biosciences' Operating Income amounted to -$6.8 million in Q3 2025, which was down 23396.34% from -$4.3 million recorded in Q2 2025.
- In the past 5 years, Castle Biosciences' Operating Income registered a high of $5.1 million during Q3 2024, and its lowest value of -$31.5 million during Q1 2023.
- Its 5-year average for Operating Income is -$11.1 million, with a median of -$8.8 million in 2021.
- As far as peak fluctuations go, Castle Biosciences' Operating Income crashed by 126589.15% in 2021, and later surged by 17158.01% in 2024.
- Quarter analysis of 5 years shows Castle Biosciences' Operating Income stood at -$15.2 million in 2021, then crashed by 50.5% to -$22.8 million in 2022, then skyrocketed by 75.22% to -$5.7 million in 2023, then surged by 171.58% to $4.0 million in 2024, then plummeted by 268.0% to -$6.8 million in 2025.
- Its Operating Income was -$6.8 million in Q3 2025, compared to -$4.3 million in Q2 2025 and -$27.9 million in Q1 2025.